These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 8500246

  • 41. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
    John R, Kamdar F, Liao K, Colvin-Adams M, Miller L, Joyce L, Boyle A.
    J Thorac Cardiovasc Surg; 2008 Nov; 136(5):1318-23. PubMed ID: 19026822
    [Abstract] [Full Text] [Related]

  • 42. Antithrombotics in heart failure with reduced ejection fraction and normal sinus rhythm: an evidence appraisal.
    Prom R, Usedom JE, Dull RB.
    Ann Pharmacother; 2014 Feb; 48(2):226-37. PubMed ID: 24259641
    [Abstract] [Full Text] [Related]

  • 43. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.
    Cohn JN, Tam SW, Anand IS, Taylor AL, Sabolinski ML, Worcel M, A-HeFT Investigators.
    J Card Fail; 2007 Jun; 13(5):331-9. PubMed ID: 17602978
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Current perspectives on hydralazine and nitrate therapies in heart failure.
    Cole RT, Gupta D, Butler J.
    Heart Fail Clin; 2014 Oct; 10(4):565-76. PubMed ID: 25217432
    [Abstract] [Full Text] [Related]

  • 48. The impact of race on response to RAAS inhibition.
    Wallace TW, Drazner MH.
    Curr Heart Fail Rep; 2005 Aug; 2(2):72-7. PubMed ID: 16036054
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial).
    Yancy CW, Ghali JK, Braman VM, Sabolinski ML, Worcel M, Archambault WT, Franciosa JA.
    Am J Cardiol; 2007 Aug 15; 100(4):684-9. PubMed ID: 17697829
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure.
    Garg RK, Gheorghiade M, Jafri SM.
    Prog Cardiovasc Dis; 1998 Aug 15; 41(3):225-36. PubMed ID: 9872608
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Current concepts in the treatment of congestive heart failure.
    Levine TB.
    Br J Clin Pharmacol; 1984 Aug 15; 18 Suppl 2(Suppl 2):147S-150S. PubMed ID: 6099731
    [No Abstract] [Full Text] [Related]

  • 58. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients.
    Cioffi G, Pozzoli M, Forni G, Franchini M, Opasich C, Cobelli F, Tavazzi L.
    Eur Heart J; 1996 Sep 15; 17(9):1381-9. PubMed ID: 8880024
    [Abstract] [Full Text] [Related]

  • 59. Vasodilator therapy in congestive heart failure.
    N Engl J Med; 1986 Nov 06; 315(19):1227-8. PubMed ID: 3762645
    [No Abstract] [Full Text] [Related]

  • 60. The risk of thromboembolism in heart failure: does it merit anticoagulation therapy?
    Shantsila E, Lip GY.
    Am J Cardiol; 2011 Feb 15; 107(4):558-60. PubMed ID: 21295173
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.